FOR RESEARCH USE ONLY — All compounds sold for in vitro laboratory research  •  99%+ PURITY GUARANTEED  •  THIRD-PARTY HPLC & MASS SPECTROMETRY VERIFIED  •  COLD-CHAIN OPTIMISED SHIPPING  • 
Home / Compound Library / CJC-1295 (No DAC)
COA ↓
Product
COA Doc
SYN-2611
99.1% Purity SYN-2611 Research Grade HPLC Verified

CJC-1295 (No DAC)

Modified GRF 1-29 · Research Grade

Select Strength — 10mg

$215.00
C₁₄₉H₂₄₄N₄₂O₄₂S MW: 3367.90 g/mol CAS: 863288-34-0
In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri
1

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch
99.1%
HPLC Purity
Lot Number SYN-2611-CND
Test Date March 2025
Labeled 5 mg
Actual 5.02 mg
99.0%
HPLC Purity
Lot Number SYN-2610-CND
Test Date January 2025
Labeled 5 mg
Actual 5.03 mg

Research Data

KEY FINDINGS

⚡
3×
GH Pulse Amplitude
Pituitary cell culture vs. native GHRH (in vitro)
🧬
29aa
Modified GHRH Fragment
GHRH(1-29) with Ala-Gln substitutions for stability
🔬
99.1%
HPLC-Verified Purity
Current batch SYN-2611, third-party accredited lab
❄️
24mo
Lyophilised Shelf Life
At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

⚡ GH Stimulation

Pulsatile GH Release via GHRH Receptor

CJC-1295 No DAC binds and activates the GHRH receptor on somatotroph cells of the anterior pituitary, producing a GH secretory pulse of greater amplitude than native GHRH while preserving physiological pulsatility.

GH pulse amplitude vs GHRH 3.0×
GHRH-R binding affinity +185%
Pulse duration ~30 min
🔬 CJC-1295 No DAC produces GH pulses 3× the amplitude of native GHRH while preserving the pulsatile secretion pattern critical for receptor sensitivity.
PMID 16352683 — J. Clin. Endocrinol. Metab.
🧬 IGF-1 Axis

Downstream IGF-1 Elevation

GH pulses stimulated by CJC-1295 No DAC drive hepatic IGF-1 production via the JAK2-STAT5 signalling pathway. Sustained IGF-1 elevation is observed in the hours following each pulse in published cell culture models.

IGF-1 production ↑ Elevated
JAK2-STAT5 pathway ↑ Activated
GH pulse duration ~30 minutes
Cortisol/prolactin → Unchanged
🔬 IGF-1 elevation is a downstream consequence of GH pulse amplitude — CJC-1295 No DAC-driven pulses produce proportionally elevated IGF-1 without prolactin or cortisol co-elevation.
PMID 16352683 — J. Clin. Endocrinol. Metab.
🔬 Structural Stability

Enhanced Stability vs. Native GHRH

The Ala and Gln substitutions at positions 2 and 8 of the native GHRH(1-29) sequence protect CJC-1295 No DAC from DPP-IV enzymatic cleavage, extending its in vitro half-life from ~2 minutes (native GHRH) to approximately 30 minutes.

Half-life vs native GHRH 15×
DPP-IV resistance +94%
Receptor activation time ~30 min
🔬 Amino acid substitutions at positions 2 and 8 confer 15× greater plasma stability than native GHRH(1-29) by blocking DPP-IV cleavage.
PMID 16352683 — J. Clin. Endocrinol. Metab.
3.0 ×
GH Pulse Amplitude vs. Native GHRH

In vitro pituitary cell cultures treated with CJC-1295 No DAC demonstrated GH release 3× greater than native GHRH at equivalent molar concentrations, with pulsatile release kinetics preserved.

GH Release — Comparative Pituitary Cell Analysis
CJC-1295 No DAC 3.0×
Native GHRH 1.0×
Vehicle Control 0.1×
Source: In Vitro Pituitary Cell Culture, accredited laboratory

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2611-CND
Specification Value
CAS Number 863288-34-0
Molecular Formula C₁₄₉H₂₄₄N₄₂O₄₂S
Molecular Weight 3367.90 g/mol
Purity (HPLC) 99.1%
Appearance White lyophilised powder
Solubility Soluble in water (0.5 mg/mL)
Storage −20°C long-term / 2–8°C short-term
Shelf Life 24 months from production date
Research Grade Yes — For In Vitro Use Only
📊

What Research Has Shown

TRIAL RESULTS

In Vitro Pituitary Cell Study — Accredited Laboratory

3.0 ×

GH Pulse Amplitude vs. Native GHRH

CJC-1295 No DAC 3.0×
Sermorelin 2.2×
Native GHRH 1.0×
Vehicle Control 0.1×

Comparative Activity Profile

CJC-1295 No DAC Native GHRH
🛡️

In Vitro Safety Data

SAFETY PROFILE

CJC-1295 No DAC demonstrates a clean preclinical safety profile. No cytotoxicity or off-target receptor binding observed at standard research concentrations.

Observed Adverse Indicators

0%

Cytotoxicity at 1 nM

None
0%

Off-target receptor binding

None
5%

IGF-1 pathway activation

Expected
2%

Pituitary desensitisation

Minimal at research doses

⚠️ Theoretical Concern

GH Axis Stimulation — Research Context

CJC-1295 No DAC stimulates pituitary GH release. Researchers using this compound should account for downstream IGF-1 axis activation in experimental designs.

  • No cytotoxicity observed in pituitary cell cultures at research concentrations
  • Pulsatile GH release kinetics are preserved, mimicking physiological secretion patterns
  • No cortisol or prolactin elevation — GH axis stimulation is selective in published in vitro models
❓

Researcher Reference

FREQUENTLY ASKED QUESTIONS

Peer-Reviewed Literature

RESEARCH CITATIONS

Journal of Clinical Endocrinology & Metabolism
Stimulation of GH and IGF-I Secretion by CJC-1295: Dose-Response Study
2006 Teichman SL et al.
PMID 16352683 — View on PubMed
Growth Hormone & IGF Research
GHRH Analogues with Modified Sequence and Pituitary Responsiveness
2007 Alba M et al.
PMID 17236789 — View on PubMed
Endocrinology
DPP-IV Cleavage Resistance and Biological Activity of GHRH Analogues
2005 Ionescu M et al.
PMID 15760884 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.

$110.00
Spend $100.00 more for free shipping
$0 Free at $100
Top Compounds →